Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Motus GI Holdings, Inc. MOTS

Healthcare — Medical Devices
Cash Flow Champion (3y)
Growth Flags show if company had growth for consecutive years

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership
42.30%

Capital & Financial Ratios

Market Cap
0.42
Revenue
0.33
Net Income
(10.59)
Free Cash Flow
(8.41)
Net Debt
(2.64)
Current Ratio
1.74
Debt/Equity
0.75
P/E ratio
0.00
P/S ratio
0.00
P/B ratio
0.00
Past 5Y EPS Growth
48.56%
This Y EPS Growth
(10.50%)
Next Y EPS Growth
27.74%
Next 5Y EPS Growth
—
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2021 2022 2023 Q'24
Cash 22.56 14.04 4.96 4.94
Receivables 0.11 0.06 0.08 0.08
Inventory 0.50 0.49 0.25 0.23
Other 0.79 0.78 — —
23.96 15.37 5.76 5.75
2021 2022 2023 Q'24
Payables 2.58 1.97 1.84 1.50
ST’ Debt 0.43 2.53 1.03 1.63
Other 0.01 0.05 0.23 0.07
3.33 4.80 3.27 3.31
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow — ‡‡‡ ‡‡‡
Earnings — ‡‡‡ ‡‡‡
Book Value — ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 0.06 — — —
—
’23 0.06 0.11 0.09 0.06
0.32
’22 0.02 0.19 0.28 0.11
0.59
’21 0.05 0.10 0.14 0.10
0.39
’20 0.03 0.00 0.03 0.04
0.10
’19 0.00 0.00 0.00 0.10
0.11
’18 0.01 0.03 — 0.00
0.04
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (2.02) — — —
—
’23 (4.80) (2.57) (1.96) (1.86)
(11.19)
’22 (5.25) (4.56) (3.62) (4.04)
(17.47)
’21 (4.54) (3.05) (2.91) (3.92)
(14.42)
’20 (7.21) (4.14) (2.67) (2.98)
(16.99)
’19 (5.59) (4.18) (4.63) (5.52)
(19.91)
’18 (3.48) (3.79) (3.25) (4.40)
(14.93)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (2.02) — — —
—
’23 (4.84) (2.62) (1.98) (1.86)
(11.30)
’22 (5.25) (4.61) (3.78) (4.05)
(17.69)
’21 (4.68) (3.18) (3.07) (3.96)
(14.89)
’20 (7.24) (4.33) (2.68) (2.83)
(17.08)
’19 (5.63) (4.30) (4.82) (5.63)
(20.38)
’18 (3.56) (3.82) (3.34) (4.75)
(15.48)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.88) — — —
—
’23 (13.79) (6.00) (4.28) (4.48)
(15.89)
’22 (26.99) (27.89) (25.34) (11.84)
(86.06)
’21 (74.96) (29.98) (29.98) (29.98)
(161.92)
’20 (68.97) (44.98) (38.98) (35.98)
(179.91)
’19 (86.96) (77.96) (53.97) (59.97)
(275.86)
’18 (170.91) (80.96) (98.95) (101.95)
(440.78)

Target Price Range

High
‡‡‡‡‡
‡‡‡
Average
‡‡‡‡‡
‡‡‡
Low
‡‡‡‡‡
‡‡‡

Recommendation Rating

2
1
Buy
2
3
Hold
4
5
Sell
2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
— — — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 10.20 1.14 — — —
Low Price
— — — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 195.00 23.40 — — —
High Price
— — ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 49 15 — — —
Employees
— — ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.01 0.02 — — —
Revenue/Emp
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.59 0.32 ‡‡‡‡‡ ‡‡‡‡‡ —
Revenue
— — ‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (34.46%) (78.37%) — — —
Gross Margin
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (18.60) (12.87) ‡‡‡‡‡ ‡‡‡‡‡ —
EBT
— — ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3,141.39%) (4,033.54%) ‡‡‡ ‡‡‡ —
EBT Margin
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (18.60) (12.87) ‡‡‡‡‡ ‡‡‡‡‡ —
Net Income
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.17 0.93 — — —
Depreciation
— — ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ 2.74 0.39 ‡‡‡‡‡ ‡‡‡‡‡ —
Revenue/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (86.06) (15.89) ‡‡‡‡‡ ‡‡‡‡ —
Earnings/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (80.87) (13.82) — — —
Cash Flow/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.04) (0.13) ‡‡‡ ‡‡‡‡‡ —
Capex/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (81.90) (13.95) — — —
Free CF/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 13.78 3.32 — — —
Book Value/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.22 0.81 ‡‡‡‡‡ ‡‡‡‡‡ —
Shares
— — — ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡ —
PE Ratio
— — — ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.87 3.30 ‡‡‡ ‡‡‡ —
PS Ratio
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.97 0.39 ‡‡‡ ‡‡‡ —
PB Ratio
— — — ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.25) (5.12) ‡‡‡‡ ‡‡‡‡ —
EV/Sales
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.01 0.14 — — —
EV/FCF
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (17.47) (11.19) ‡‡‡ ‡‡‡‡‡ —
Op' Cash Flow
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.22) (0.10) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (17.69) (11.30) — — —
FCF
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 10.57 2.49 — — —
Working Cap'
— — — — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 11.01 2.27 — — —
Total Debt
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3.03) (2.69) — — —
Net Debt
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.98 2.69 — — —
Sh' Equity
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (85.04%) (103.47%) ‡‡‡ ‡‡‡ —
ROA
— — ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00% (744,187.50%) — — —
ROIC
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (294.40%) (454.34%) ‡‡‡ ‡‡‡ —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Motus GI Holdings (MOTS), developer of the Pure-Vu® system to boost colonoscopy prep efficiency, has endured a decade of medtech volatility since its 2019 SPAC debut, battered by COVID disruptions, commercialization stumbles, and aggressive dilution. Revenue surged from near-zero in 2017 to a 2022 peak of $592,000 (+51% YoY), but contracted 46% in 2023 amid reimbursement hurdles—yet analysts forecast a dramatic inflection: +715% to $2.6 million in 2024 and +148% to $6.45 million in 2025, driven by lean operations (revenue/employee >$21,000) and a $1B U.S. market opportunity amid rising colorectal screenings.

Chronic losses persist, with net income improving 44% to -$12.9 million in 2023 but projected wider in 2025; negative gross margins (-0.78%) and ROE at -4.54% reflect equity erosion (book value/share -76% to $3.32), though debt slashed 79% leaves a cash-rich position. Free cash flow edges toward breakeven (+$900k ops CF in 2025 forecast), signaling potential scale akin to Intuitive Surgical’s early ramps—if margins hit 60-70% norms.

Stock cratered 99%+ from 2018 highs to ~$0, with PS at 3.3x and EV/sales flipping positive, implying massive undervaluation if growth materializes—mirroring Exact Sciences’ pre-profit rewards. No insider buys temper hype, but clinician data and partnerships could unlock inflection; high-risk spec play demands monitoring Q4 revenue for 3-5x potential.

Read full commentary →

Motus GI Holdings, Inc. (MOTS) Latest News

News by impact score

Fine-tune

14 May

4 GlobeNewswire, 4:05 PM
Motus GI Holdings, Inc. reported first quarter 2024 financial results, doubled active customers for Pure-Vu system, and engaged investment bank for strategic alternatives. The engagement of an investment bank to evaluate strategic alternatives is a significant move that could fundamentally alter the company's trajectory and investor sentiment.

18 Mar

4 GlobeNewswire, 4:05 PM
Motus GI Holdings, Inc. reported financial results for Q4 and full year 2023, initiated limited U.S. commercial launch of Pure-Vu EVS Gastro and Gen 4 Colon system, and seeks strategic partnerships. Initiation of commercial launch, positive data from colonoscopy study, new patent issuance, and seeking strategic partnerships are significant moves that could impact the company's trajectory.

22 Feb

3 GlobeNewswire, 8:00 AM
Motus GI Holdings, Inc. announced the exercise of warrants for $2.7 million gross proceeds. The exercise of warrants will have a moderately noticeable influence on the company's financial position and market sentiment.

21 Feb

4 GlobeNewswire, 8:52 AM
Motus GI Holdings granted a U.S. patent for a key feature in the Pure-Vu system to avoid clogging in cleansing the GI tract. The patent for the self-purging feature in the Pure-Vu system could significantly impact Motus GI Holdings' future by enhancing endoscopic outcomes and experiences.

30 Jan

4 GlobeNewswire, 8:00 AM
Motus GI Holdings published positive results from a European study on the Pure-Vu System for colonoscopy in patients with poor bowel preparation. The positive study results and enhancements to the Pure-Vu System are expected to significantly impact Motus GI Holdings' future performance and market position.

7 Jan

3 Simply Wall St., 3:56 AM
Motus Holdings' returns on capital have decreased over the past five years, but the company is reinvesting for growth with higher sales. The article suggests that while there may be a noticeable influence on key areas like financial performance, the overall effect is expected to be somewhat limited.

21 Dec

3 Simply Wall St., 7:36 AM
Motus Holdings Limited (JSE:MTH) share price has increased by 66% in the last three years, outperforming the market return of 16%. The article suggests that the company's EPS growth has outpaced the share price increase, indicating a cautious sentiment in the market.

18 Dec

3 GlobeNewswire, 10:10 PM
Motus GI Holdings, Inc. priced a $5.0 million public offering of common stock and warrants. The public offering may moderately influence the company's financial performance and market positioning.

4 Dec

3 Simply Wall St., 11:30 PM
Motus Holdings Limited (JSE:MTH) achieved a 19% ROE with the use of debt. The article highlights the impact of debt on the company's ROE, which could moderately influence its financial performance.

19 Nov

3 Simply Wall St., 3:35 AM
Motus Holdings Limited saw a double-digit share price rise on the JSE, but may be fairly priced according to valuation model. The article suggests that Motus Holdings' earnings growth is expected to be in the teens in the upcoming years, indicating a solid future ahead.

13 Nov

4 GlobeNewswire, 4:05 PM
Motus GI Holdings, Inc. reports third quarter financial results and FDA clearance for Pure-Vu EVS Gastro system. FDA clearance and market introductions of Pure-Vu EVS Gastro system expected to have a significant impact on future commercialization and stockholder value.

10 Nov

4 GlobeNewswire, 8:00 AM
Motus GI announces first upper GI patient procedure for FDA cleared Pure-Vu EVS Gastro. FDA clearance of Pure-Vu EVS Gastro for upper GI market with high unmet clinical need and potential to address 400,000 cases of upper GI bleeds per year in the U.S.

2 Nov

3 Simply Wall St., 12:03 AM
Motus Holdings CEO's pay packet and performance highlighted ahead of AGM. CEO's compensation and company's growth numbers may moderately influence future performance.

24 Oct

4 GlobeNewswire, 8:00 AM
Motus GI Holdings, Inc. receives FDA clearance for Pure-Vu EVS Gastro and Gen 4 Colon system. FDA clearance for new system with enhanced features expected to significantly impact market adoption and clinical outcomes.

23 Oct

3 Simply Wall St., 6:35 AM
Institutional investors dominate ownership of Motus Holdings, with top 5 shareholders holding 53% of the company. Institutional ownership can moderately influence company decisions and market sentiment.

26 Sep

4 GlobeNewswire, 8:00 AM
Motus GI submitted a special 510(k) to FDA for Pure-Vu EVS Gen 4 Gastro and Colon. The submission of the special 510(k) for the new Pure-Vu Gen 4 platform could significantly impact Motus GI's future market performance and competitive positioning.

14 Sep

4 GlobeNewswire, 4:05 PM
Motus GI cancels $1.0M royalty obligations by exchanging for common stock. Cancellation of royalty obligations and potential financing alternatives could significantly impact Motus GI's future performance.

6 Sep

3 GlobeNewswire, 5:00 PM
Motus GI appoints Scott Durbin to its Board of Directors as David Hochman and Darren Sherman resign. Appointment of Scott Durbin may have a moderately noticeable influence on Motus GI's future strategic and financial decisions.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us